ELUTIA INC. - CLASS A COMMON STOCK

Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance

09 May 2024 16:05:01 By Nasdaq GlobeNewswire

Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

02 May 2024 16:05:00 By Nasdaq GlobeNewswire

Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1

24 Apr 2024 16:05:00 By Nasdaq GlobeNewswire

Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024

22 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Elutia Regains Compliance with Nasdaq Listing Requirements

10 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Elutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA Clearance

18 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results

13 Nov 2023 16:05:01 By Nasdaq GlobeNewswire

Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

09 Nov 2023 08:30:00 By Nasdaq GlobeNewswire

Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

06 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Elutia to Participate in a Panel Discussion at the Cantor Global Healthcare Conference

20 Sep 2023 08:30:00 By Nasdaq GlobeNewswire

Elutia Announces Private Placement for Proceeds Up to $26 Million

19 Sep 2023 08:36:23 By Nasdaq GlobeNewswire

Elutia Announces Sale of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

18 Sep 2023 16:08:42 By Nasdaq GlobeNewswire

Elutia to Present at the H.C. Wainwright 25th Annual Global Investment Conference

08 Sep 2023 08:30:00 By Nasdaq GlobeNewswire

Aziyo Biologics Rebrands as Elutia to Reflect Strategic Focus on Drug Eluting Biomatrices

06 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures

30 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company

14 Aug 2023 16:05:01 By Nasdaq GlobeNewswire

Aziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

31 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

Aziyo Biologics Announces Voluntary Recall of Viable Bone Matrix Products

13 Jul 2023 16:30:00 By Nasdaq GlobeNewswire

Aziyo Biologics Presents Positive Clinical Data on CanGaroo® Biologic Envelope

19 May 2023 08:15:00 By Nasdaq GlobeNewswire

Aziyo Biologics Reports Highest Sales and Gross Profit in Company History

10 May 2023 16:05:01 By Nasdaq GlobeNewswire